Problem Solving in Cardiovascular Risk

Description:
This title will help the multiplicity of clinicians who treat increasing numbers of patients with established cardiometabolic disease. It reflects the experiences and challenges that the authors have seen in leading lipid and prevention clinics in primary and secondary care over the last two decades. It will aid in providing answers for those seeking strategies to manage this complex range of symptoms.

Benefits:
* Case-study approach with over 50 clinical presentations enables doctors to apply scientific knowledge to real-life patients * Comprehensive coverage of primary and secondary prevention, hyperlipidaemias and hypertension * CPD and group training resource for students and experienced clinicians

Readership:
Specialists in cardiology and internal medicine * General physicians * Doctors in training

Table of Contents:

Abbreviations
Introduction
Part I: Primary Prevention
1. Assessment of cardiovascular risk
2. Obesity
3. Metabolic syndrome
4. Vegetarian
5. Indian Asian
6. Afro-Caribbean/African
7. Polygenic hyperlipidaemia
8. Elderly
9. Women
10. Family screening
11. IGT to diabetes
12. Low HDL-C
13. Combination therapy (statin-fibrate)
14. Combination therapy (statin-niacin)

Part II: Secondary prevention
15. Coronary heart disease-stable
16. Coronary heart disease-ACS
17. Stroke
18. Peripheral vascular disease
19. Aortic stenosis
20. Erectile dysfunction
21. Atrial fibrillation
22. Renal artery stenosis
23. Homocysteine
24. Diabetes type 1
25. Diabetes type 2
26. DM & Microalbuminuria
27. High Lp(a)
28. Cardiac Failure

Part III: Secondary Hyperlipidaemias and side-effects
29. Hypothyroid
30. Alcohol (binge)
31. Non-alcoholic fatty liver disease
32. Myositis/rhabdomyolysis
33. Gallstones/primary biliary cirrhosis
34. Unable to tolerate anything
35. Gastrointestinal drug intolerance
36. Neuropathy

Part IV: Genetic Hyperlipidaemias
37. Familial Hypercholesterolaemia
38. Paediatric familial hypercholesterolaemia
39. Homozygous familial hypercholestreolaemia
40. Familial Combined Hyperlipidaemia
41. Remnant Hyperlipidaemia (E2/E2)
42. Chylomicronaemia (type I/V)
43. Glycogen storage disease
44. Fabry’s disease

Part V: General Medicine and Hyperlpidaemia
45. Pregnancy & pancreatitis
46. HIV
47. SLE/Rheumatoid arthritis/seronegative arthritis
48. Nephrotic syndrome
49. Chronic renal failure
50. Renal transplant
51. Growth hormone/pituitary deficiency

Part VI: Hypertension
52. Essential Hypertension
53. Difficult isolated systolic hypertension
54. Phaeochromocytoma
55. Hyperaldosteronism

Part VII: Dermatological Dyslipdaemia
56. Retinoid-induced dyslipidaemia
57. Mycosis fungoides, bexarotene and T-cell lymphoma

General index

Authors:
MA Crook, Guy’s & St Thomas’ Hospitals, London, UK; R Minhas, Clinical Director, BMJ Evidence Centre, London, UK; TM Reynolds, Queen’s Hospital, Burton-on-Trent, UK; PJ Twomey, Ipswich Hospital, Ipswich, UK; A Viljoen, Lister Hospital, Stevenage, UK; AS Wiezerbicki, Guy’s & St Thomas’ Hospitals, London, UK.